Advertisement
Advertisement
CLNN
Clene Inc. Common Stock
5.44
USDSponsored
-0.29
-5.06%
Mar 25, 16:00 UTC -4
Closed
After-Market
5.51
+0.07
+1.38%
CLNN Earnings Reports
Positive Surprise Ratio
CLNN beat 11 of 21 last estimates.
52%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$41.41K
/-$0.63
Implied change from Q4 25 (Revenue/ EPS)
-46.22%
/-28.41%
Implied change from Q1 25 (Revenue/ EPS)
-48.87%
/+600.00%
Clene Inc. Common Stock earnings per share and revenue
On Mar 12, 2026, CLNN reported earnings of -0.88 USD per share (EPS) for Q4 25, missing the estimate of -0.59 USD, resulting in a -47.23% surprise. Revenue reached 77.00 thousand, compared to an expected 36.98 thousand, with a 108.25% difference. The market reacted with a +6.09% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.63 USD, with revenue projected to reach 41.41 thousand USD, implying an decrease of -28.41% EPS, and decrease of -46.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Sutro Biopharma, Inc.
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$4.43
Actual
-$5.29
Surprise
-19.39%
Aardvark Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.84
Actual
-$0.81
Surprise
+4.64%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
MAIA Biotechnology, Inc.
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.09
Surprise
+32.13%
Abivax SA - ADR
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.52
Actual
-$3.24
Surprise
-112.47%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Clene Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Clene Inc. Common Stock reported EPS of -$0.88, missing estimates by -47.23%, and revenue of $77.00K, 108.25% above expectations.
How did the market react to Clene Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 6.09%, changed from $5.58 before the earnings release to $5.92 the day after.
When is Clene Inc. Common Stock expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Clene Inc. Common Stock's next earnings report?
Based on 5
analysts, Clene Inc. Common Stock is expected to report EPS of -$0.63 and revenue of $41.41K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement